Fratricide-resistant CD7-CAR T cells in T-ALL
- 3 September 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (12) , 3687-3696
Abstract
T cell acute lymphoblastic leukemia (T-ALL) is difficult to treat when it relapses after therapy or is chemoresistant; the prognosis of patients with relapsed or refractory T-ALL is generally poor. We report a case series of 17 such patients who received autologous chimeric antigen receptor (CAR) T cells expressing an anti-CD7 CAR and an anti-CD7 protein expression blocker (PEBL), which prevented CAR T cell fratricide. Despite high leukemic burden and low CAR T cell dosing, 16 of the 17 patients attained minimal residual disease-negative complete remission within 1 month. The remaining patient had CD7− T-ALL cells before infusion, which persisted after infusion. Toxicities were mild: cytokine release syndrome grade 1 in ten patients and grade 2 in three patients; immune effector cell-associated neurotoxicity syndrome grade 1 in two patients. Eleven patients remained relapse-free (median follow-up, 15 months), including all nine patients who received an allotransplant. The first patient is in remission 55 months after infusion without further chemotherapy or transplantation; circulating CAR T cells were detectable for 2 years. T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially an effective option for the treatment of T-ALL.Keywords
Funding Information
- MOH | National Medical Research Council (CSA/0053/2013, CSA/0053/2008, RTF/MOH/000616, RTF/MOH/000302, Singapore Translational Research (STaR) Award MOH-000708)
This publication has 64 references indexed in Scilit:
- Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with CD7‐targeted chimeric antigen receptor‐T cell therapyAmerican Journal of Hematology, 2023
- The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domainsMolecular Therapy, 2021
- Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trialsEuropean Journal of Cancer, 2021
- Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemiaThe Lancet Oncology, 2019
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyNature Medicine, 2017
- Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignanciesNature Medicine, 2017
- Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphomaAmerican Journal of Hematology, 2017
- Therapeutic T cell engineeringNature, 2017
- Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemiaThe Lancet Oncology, 2009
- Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective studyThe Lancet, 2005